Ralph Solarski Image crop BW.jpg

Ralph solarski

Chief Executive Officer

Ralph Solarski is the founder of Relevale Inc. and serves as its Chairman and CEO.  Mr. Solarski has thirty years’ experience developing and commercializing innovative products, including over two dozen new product launches. He brings broad functional experience with accomplishments in business development, strategy, R&D, marketing, sales and operations. Previously, Mr. Solarski led business development and strategy for a novel microneedle drug delivery technology at Kimberly-Clark. He earned his M.B.A. in Marketing from the UNC Kenan-Flagler Business School and his B.B.A. degree in Finance from the University of Notre Dame.

Bob Malone Image BW.jpg

Bob malone

Chief Technical Officer

Bob Malone serves as the Chief Technical Officer for Relevale. Mr. Malone has twenty-five years of pharmaceutical product development and commercialization expertise, including the development and launch of several marketed products. He brings a broad range of skills and capabilities in chemistry, manufacturing and controls (CMC) across product development, quality, analytical chemistry, process development, outsourcing and operations. Mr. Malone combines strategic planning acumen with a results-driven, time-and-cost focused management style. He earned his M.S. in Analytical Chemistry from the University of Massachusetts and his B.S. in Chemistry from Framingham State University.

Joe Dillon Image BW.jpg

joe dillon, Ph.d, mba

Chief Financial Officer

Joe Dillon serves as the Chief Financial Officer, bringing over twenty years’ experience in the pharmaceutical industry. He has accomplishments in global business development, planning and analysis, corporate finance, M&A, licensing and technology valuations. He has participated in the valuations of over four hundred deals including forty transactions that closed. At prior companies, Dr. Dillon has held the positions of CEO, President, CFO, Secretary and Treasurer. Dr. Dillon is a past-chairperson of the Licensing Executive Society, Life Sciences Sector and is a veteran speaker at industry organization events such as BIO, BIO-Europe and LES (Licensing Executives Society). Dr. Dillon holds a Ph.D. in Metaphysical Sciences from UMS, an M.B.A. in International Finance from Kansas State University and a B.B.A. in Finance from Washburn University.

Dimitrios Angelis Image BW.jpg

dimitrios angelis

General Counsel and Secretary

Dimitrios Angelis serves as the General Counsel and Secretary for Relevale. During Mr. Angelis’ 15 years in the life science industry, he has worked as both General Counsel and outside counsel, and advised and represented clients from start-ups to mid-sized firms to large multi-nationals in many types and sizes of transactions including M&A, SEC matters, contracts, regulatory affairs and employment law. He brings a strong business acumen, including experience as a CEO of a Nasdaq public company, and currently sits on several public company boards. Mr. Angelis earned his J.D. from New York University, his M.A. in Behavioral Studies from California State University and his B.A. from Boston College.

David Lin Image BW.jpg

david lin, ph.d.

Head of Regulatory Affairs

David Lin provides strategic direction and tactical management of the Regulatory Affairs for Relevale.  Dr. Lin has twenty-three years of pharmaceutical industry experience in the regulatory requirements for small molecule drugs, biologic drugs and combination products. Dr. Lin’s regulatory product development expertise was developed at FDA while working as a CMC reviewer, CMC Team Leader, acting Deputy Division Director, and acting Division Director in the Office of New Drug Chemistry in the Center for Drug Evaluation and Research (CDER), and in the Center for Biologics Evaluation and Research (CBER). Dr. Lin earned his Ph.D. in organic chemistry from the University of Maryland, his MBA in Finance from the Robert H. Smith School of Business at the University of Maryland and his B.A. in Biochemistry from the University of Pennsylvania.

Kati Chupa Image BW.jpg

kati chupa

Head of Commercial Planning

Kati Chupa brings an extensive background in pharmaceutical marketing, business development and sales to Relevale. She has held board level leadership positions across multiple disciplines and Therapeutic Areas with Janssen Pharmaceuticals/Johnson & Johnson. She has served as Vice President of Marketing, Vice President of Global Early Strategic Marketing and Vice President of Strategy/Portfolio. Kati earned her M.B.A. in Marketing and B.S. in Business Administration from the University of Tulsa.

 

Damon Cook Image BW.jpg

damon cook

Head of Human Factors and Usability Engineering

Damon Cook leads the Human Factors and Usability Engineering function at Relevale.  Mr. Cook’s ten years’ experience includes accomplishments in the areas of formative and summative studies for combination products, FDA regulatory submissions and study facilitation, reporting and analysis. He led human factors and usability engineering projects at Amgen, including both prefilled syringes and autoinjectors for home administration. Mr. Cook earned his M.S. in Computer Science/Human Computer Interaction from the University of Illinois and his B.S. in Computer Science from New Mexico State University.  

Bob Binder BW.jpg

Bob binder

Head of Market Access Planning

Bob Binder provides strategic and tactical planning for market access at Relevale.  During Bob’s thirty years in the pharmaceutical industry he has developed and implemented numerous market access strategies. He has led regional and national managed market teams and developed and implemented value-based health management programs and adherence/compliance programs.  He has extensive experience in negotiating and contracting with regional and national managed care organizations including Express Scripts, CVS Caremark, Cigna and Aetna. Bob earned his B.S. in Business Management from Arizona State University.


In addition to the Leadership Team shown, Relevale obtains medical advice from key opinion leaders in the medical community. A leading expert in the field of RLV-113 has been an active contributor in its planning and development.